About
We are an early stage company focused on advancing our lead platform: LuCI™ AJN 003, an oral drug that replicates the metabolic success of bariatric surgery in treated of Type 2 Diabetes.
Tags
We are an early stage company focused on advancing our lead platform: LuCI™ AJN 003, an oral drug that replicates the metabolic success of bariatric surgery in treated of Type 2 Diabetes.